News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
September 15
Salt Lake City, Sep. 15, 2021 (GLOBE NEWSWIRE) —Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative...
-
September 14Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs
Salt Lake City – September 14, 2021 – Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information...
-
September 13
Salt Lake City – September 13, 2021 – Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...
-
August 30
Salt Lake City – August 30, 2021 – Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
-
August 17Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare
SALT LAKE CITY, Aug. 17, 2021 (GLOBE NEWSWIRE) — Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
-
July 14
Salt Lake City – July 14, 2021 – Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
-
May 19– The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time
SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) — Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy...
-
May 18– Data presented at the ISPOR 2021 Conference illustrating clinical benefit as well as cost savings
Salt Lake City – May 18, 2021 – Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to...
-
April 28– Several prominent healthcare-focused institutional investors fund Sera to expand commercialization of the PreTRM® Test –
SALT LAKE CITY, April 28, 2021 (GLOBE NEWSWIRE) — Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative...
-
April 13– Highly accomplished attorney joins Sera to develop its legal and intellectual property functions –
SALT LAKE CITY, April 13, 2021 (GLOBE NEWSWIRE) — Sera Prognostics, Inc., The Pregnancy Company®, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
-
March 31– Accomplished technology leader joins Sera to build and deploy its information strategy –
Salt Lake City – March 31, 2021 – Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to...
-
February 15
February 15, 2021 — Sera Prognostics, Inc., a leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, will be presenting at...
-
February 03– Receipt of dedicated CPT® code marks important commercialization milestone to pursue reimbursement for the PreTRM® Test –
Salt Lake City – February 3, 2021 – Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches,...
-
January 05– Patient enrollment began in November for this rigorous prospective, randomized, controlled PRIME intervention trial to demonstrate the value of implementing the PreTRM® prevention strategy to improve neonatal outcomes and lower cost of care-
SALT LAKE CITY, January 5, 2021 (GLOBE NEWSWIRE) — Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker...
Sign up for our investor relations email list here.